Regencell Bioscience HoldingRGC
13F holders, Q4 2024 (December 31)3holders +1
1new positions
0sold out
$4.94avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding Regencell Bioscience Holding (RGC) in their 13F filings, up 1 from Q3 2024. 1 opened new positions and 0 sold out. The largest holders were UBS Group AG ($144K), Morgan Stanley ($10K) and BlackRock, Inc. ($1K).
- Company
- Regencell Bioscience Holding
- CUSIP
- G7487R100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $10K |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 13,442 shares bought, net +13,442 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| UBS Group AG | 0.00% | Add +63.5% | 29,218 | $144K |
| Morgan Stanley | 0.00% | New | 2,100 | $10K |
| BlackRock, Inc. | 0.00% | No change | 238 | $1K |
"% of holder's portfolio" is RGC's weight in each manager's 13F, not the share of Regencell Bioscience Holding the manager owns.